Travera Inc
3 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs (NCT04985357) | Travera Inc | 2024-11-01 |
| Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx) (NCT05461430) | Travera Inc | 2022-07-15 |
| Mass Accumulation Rate (MAR) as a Predictive Biomarker in Multiple Myeloma (NCT03777410) | Travera Inc | 2019-02-11 |
Track Travera Inc automatically
Every clearance here is in the API, with alerts when new ones post.